What Happened?
Lincolnshire, IL-based Melinta has Promoted Mary T. Szela as Chief Executive Officer
About the Company
Melinta Therapeutics, Inc. (NASDAQ:MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.
About the Person
\r\n Mary T. Szela joined Melinta Therapeutics as director in January 2013 and was named chief executive officer in April 2013. Ms. Szela is an accomplished pharmaceutical executive with a 25-year history of consistently creating growth, generating positive organizational change and inspiring high-performing teams. Most recently, she was senior vice president of global strategic marketing and services in the Abbott Laboratories Pharmaceutical Products group. From 2008 to 2010, Ms. Szela was the senior vice president, U.S. pharmaceuticals at Abbott Laboratories. In this role, she was directly responsible for Abbott`s $8 billion dollar U.S. pharmaceutical business where she directed the development and launch of more than eight new pharmaceutical products and multi-billion dollar sales growth for Abbott`s flagship product, Humira®. Prior to this role, she managed several of Abbott`s U.S. pharmaceutical businesses including Abbott`s $1.5 billion anti-infective franchise, including Biaxin®, an oral antibiotic used to treat a spectrum of Gram-positive and Gram-negative bacteria. Under her management, sales of Omnicef®, a broad-spectrum antibiotic grew from $50 million in 2001 to over $850 million in 2007, when it became available as a generic. Prior to 2001, Ms. Szela held a series of leadership positions in the Abbott Hospital Products division where she was responsible for the peri-operative, intensive care and pain management pharmaceutical business, the global One 2 One™ outsourcing business, critical care device business and the vascular medicine pharmaceutical business. In her management of the One 2 One business, Ms. Szela lead the effort to out-license Abbott`s ADD-Vantage®, a two-part I.V. bag-filling system designed to increase flexibility in drug preparation. ADDVantange was outlicensed to Merck, Johnson & Johnson and other pharmaceutical companies to deploy with their I.V. anti-infectives. Ms. Szela is a member of the Boards of Novo Nordisk, Suneva Medical, Coherus BioSciences, and Receptos, Inc. In addition to her professional responsibilities, she is a passionate advocate for children`s issues and sits on the Board of Directors for CASA Lake County (court appointed advocates for children in Illinois). A former trauma nurse, Ms. Szela earned a bachelor`s degree in nursing and an Master of Business Administration from the University of Illinois.\r\n
Info Source
News
Short Profile